Drug Profile


Alternative Names: JNJ 39659100; MBX-102; Metaglidasen

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Metabolex
  • Developer CymaBay Therapeutics; Metabolex
  • Class Amides; Antigouts; Antihyperglycaemics; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gout
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 03 Jan 2017 Arhalofenate licensed to Kowa Pharmaceuticals for the treatment of Gout in USA
  • 18 Jul 2016 Biomarkers information updated
  • 28 Mar 2016 Updated Efficacy data from a phase IIb trial in Gout released by CymaBay Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top